Interval between two doses of Covishield increased to 4-8 weeks
State officials said the recommendation came from the National Technical Advisory Group on Immunisation (NTAGI) and National Expert Group on Vaccine Administration for Covid-19 (NETVAG) based on several studies.
Until now, recipients received a reminder message 28 days after the first dose to visit the centre for their second dose. A recipient had the choice to stretch the second dose to upto 42 days. (Express photo)
The central government on Monday revised the time interval between two doses of Covishield, directing states to increase it to 4-8 weeks from the current protocol of 4-6 weeks.
The Union Ministry of Health and Family Welfare took the decision on the recommendation of two expert groups — the National Technical Advisory Group on Immunisation (NTAGI) and National Expert Group on Vaccine Administration for Covid-19 (NEGVAC).
You’ve Read Your Free Stories For Now
Sign up and keep reading more stories that matter to you.
“During this meeting the recommendation has been revised to provide 2nd dose of COVISHIELD at 4-8 weeks’ interval after the first dose, instead of earlier practised interval of 4-6 weeks. This decision of revised time interval between two doses is applicable ONLY to COVISHIELD and NOT to COVAXIN vaccine,” the Ministry said.
Union Health Secretary Rajesh Bhushan wrote to states that based on the scientific evidence, it “appears that protection is enhanced if the second dose of COVISHIELD is administered between 6-8 weeks, but not later than stipulated period of 8 weeks”.
Data on the Co-WIN dashboard show 4.22 crore doses of Covishield have been administered so far during the country’s vaccination drive. Of the total 4,61,07,627 doses administered, including both Covishield and Covaxin, the second dose has been given to only 74,84,953 beneficiaries so far. After Monday’s announcement, the schedule for the second dose will change for all Covishield recipients in this group.
India’s decision comes in the backdrop of global trials that have shown that an extended interval of up to 12 weeks demonstrated greater efficacy in the Oxford-AstraZeneca vaccine, of which Covishield is a version. The trials have also suggested that administering the second dose with an interval longer than four weeks could further increase efficacy. Importantly, delaying the second dose allows a larger number of people to get their first shots of the vaccine sooner.
Explained
Greater vaccine efficacy
India’s decision on the second dose for Covishield comes after the WHO’s expert team recommended that a longer interval between 8 and 12 weeks between the two doses are associated with greater vaccine efficacy. Britain was the first country to extend the interval between the initial and booster doses of the AstraZeneca vaccine to 12 weeks.
On Monday, AstraZeneca announced the results of phase 3 trials of the vaccine in the United States, which demonstrated 79 per cent efficacy at preventing symptomatic Covid-19 and 100% efficacy at preventing severe disease and hospitalisation.
“Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80 per cent,” the company said.
The interim safety and efficacy analysis announced on Monday is based on 32,449 participants, accruing to 141 symptomatic cases of Covid-19.
The US results come at a time when there is concern over instances of blood clots among some European beneficiaries vaccinated with the AstraZeneca shot. The company said the safety board had specifically conducted a review of the thrombotic events, and found no risk during the US trials.
“The vaccine was well tolerated, and the independent data safety monitoring board (DSMB) identified no safety concerns related to the vaccine. The DSMB conducted a specific review of thrombotic events, as well as cerebral venous sinus thrombosis (CVST) with the assistance of an independent neurologist. The DSMB found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial,” the company said in its release.
As City Editor ( Delhi) at the Indian Express, Kaunain Sheriff leads city reporting with a sharp focus on accountability journalism, data-driven stories, and ground-level impact. As the National Health Editor he leads the newsroom’s in-depth coverage of pressing health issues.
He is the author of Johnson & Johnson Files: The Indian Secrets of a Global Giant, a definitive investigation into the accountability of one of the world’s most powerful pharmaceutical corporations.
Areas of Expertise
Investigative Reporting: Has deep expertise in investigative reporting spanning public health, regulatory affairs, drug safety, and the criminal justice system. His work sits at the intersection of governance, law, and accountability, with a particular focus on how regulatory failures, institutional lapses, and policy decisions affect citizens’ rights and safety.
Data Journalism: Has extensively on big data–driven investigations, including analyses of flagship government schemes and large datasets on criminal trials, uncovering systemic gaps.
Global Collaborations
Kaunain is a key contributor to major international journalistic projects:
The Implant Files: Collaborated with the International Consortium of Investigative Journalists (ICIJ) to expose global malpractices in the medical device industry.
Chinese Big-Data Investigation: Uncovered how a foreign data firm monitored thousands of prominent Indian institutions and individuals in real-time.
Awards & Recognition
His commitment to "Journalism of Courage" has been recognized with the industry's highest honors:
Ramnath Goenka Award for Excellence in Journalism
SOPA Award (Society of Publishers in Asia)
Red Ink Award (Mumbai Press Club)
Indian Express Excellence Awards (Triple recipient for investigations into the NSA abuse in UP, Vyapam scam, and the anti-Sikh riots).
Education: Studied Mechanical Engineering at Visvesvaraya Technological University (VTU), Bangalore, before moving to Delhi to pursue his passion for journalism. His engineering training informs his analytical approach, enabling him to decode technical, legal, and data-heavy systems with precision.
Social media
LinkedIn: linkedin.com/in/kaunain-sheriff-3a00ab99
X ( fromerly Twitter): @kaunain_s ... Read More
